SHIRLEY, N.Y., Feb. 3, 2011 /PRNewswire/ -- American Regent is conducting a nationwide voluntary recall to the consumer and user level of the following product:Potassium PhoshaesInjection,USP,15mM/5 mLPhoshorus;22mEq/5mLoassium5mLSingleDoseVialNDC# 0517-2305-25Lot # 0048ExpDate: January,2012PLEASE NOTE: This recall, initiated on February 3, 2011 to the User or Consumer Level, is for lot # 0048 Only. No other lots or sizes of Potassium Phosphates Injection, USP are subject to this voluntary recall.This voluntary recall was initiated because some vials of this lot exhibit translucent visible particles consistent with glass delamination.
Potential adverse events after intravenous administration include damage to blood vessels in the lung, localized swelling, and granuloma formation. American Regent is undertaking this recall in consideration of the potential for safety issues if this lot of product is administered to patients.
Potassium Phosphates Injection, USP, 3 mM Phosphorus/mL, is indicated as a source of phosphorus, for addition to large volume intravenous fluids to prevent or correct hypophosphatemia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formulas when the needs of the patient cannot be met by standard electrolyte or nutrient solutions.
The product was distributed to wholesalers and distributors nationwide.
Hospitals, Home Health Care Agencies, Emergency Rooms, Infusion Centers, Clinics and other healthcare facilities should not use American Regent, Inc., Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, with lot # 0048 for patient care and should immediately quarantine any product for return.
American Regent is notifying its distributors and consumers by email, facsimile and/or overnight courier and is arranging for return of all recalled product. Consumers/distributors/retailers that have product which is being recalled should stop use.
AmericanRegentwill creditaccountsfoall eturned producwith this lot#. Thosewith questionsabout thereturnor ecallprocess, pleasecall our CustomeServiceDepartmenat 1-877-788-3232: Monday thu Friday fom8:30AMto7:00PMEST.Hositals, Home Health Agencies, Emegency ooms, Infusion Centers, Clinics and Healthcare Providers,or patients withproduct quality complains, medicalor ohequestions concerning the useof he product or reasons for his recall should contact the Pofessional SevicesDepartmena1-877-788-3232.Anyadvese reactions experiencedwiththe use of this poduct should be reported to AmericanRegent,Inc.viaemailat firstname.lastname@example.org (610)650-7781or (610)650-0170oryhonea1-800-734-9236. TOEXPEDITE HANDLINGPLEASE DONOT REPO ANYTHINGOTHETHANSPECIFIC ADVERSE EVENTS TO THIS EMAIL ADDRESS OR FAX O PHONE.Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.
"All of us at American Regent and Luitpold are taking the necessary steps to protect patients from any potential safety risks with our Potassium Phosphates Injection. The safety and well being of patients receiving our products is our primary concern," said Mary Jane Helenek, President and CEO of American Regent.
While American Regent continues to investigate this issue, the company is taking precautionary action and initiated this voluntary recall. American Regent has informed the FDA of its actions and is maintaining ongoing discussions with the agency.
As is standard practice, and as stated in the Potassium Phosphates Injection, USP, Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."
Potassium Phosphates Injection, USP is manufactured by Luitpold Pharmaceuticals, Inc. and is distributed by American Regent, Inc. (Shirley, NY).
Source: Luitpold Pharmaceuticals, Inc.
This voluntary recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
|SOURCE Luitpold Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved